FIDELITY预设探索性分析:非奈利酮在慢性肾脏病合并2型糖尿病患者中的使用与肾脏结局
FIDELITY是FIDELIO-DKD与FIGARO-DKD的预设汇总分析,纳入13026例慢性肾脏病合并2型糖尿病患者,中位随访3年。非奈利酮较安慰剂显著降低肾脏复合结局风险23%(HR 0.77,95%CI 0.67-0.88)及终末期肾病风险20%(HR 0.80,95%CI 0.64-0.99),两组不良事件相似,但非奈利酮组因高钾血症停药更常见。
要点
- 非奈利酮降低肾脏复合结局风险23%(HR 0.77)。
- 非奈利酮降低终末期肾病风险20%(HR 0.80)。
- 因高钾血症停药非奈利酮组更常见,eGFR<60组2.4% vs 0.8%。
核心结论
- 非奈利酮改善慢性肾脏病合并2型糖尿病患者的肾脏结局,降低终末期肾病风险,且耐受性良好。
研究设计与样本
- FIDELITY为FIDELIO-DKD与FIGARO-DKD研究的预设汇总分析,纳入13026例慢性肾脏病合并2型糖尿病患者,中位随访3年。
主要发现
- 非奈利酮较安慰剂显著降低肾脏复合结局(肾脏衰竭、eGFR较基线持续下降57%或以上、肾脏死亡)风险23%(HR 0.77,95%CI 0.67-0.88),3年绝对组间差异1.7%(95%CI 0.7-2.6)。
- 预设基线eGFR和尿白蛋白-肌酐比值分类的HR方向一致(交互作用P分别为0.62和0.67),但尿白蛋白-肌酐比值30-300 mg/g亚组不确定性高。
- 非奈利酮较安慰剂显著降低终末期肾病风险20%(HR 0.80,95%CI 0.64-0.99)。
- 不良事件两组相似,但导致停药的高钾血症非奈利酮组显著更常见:eGFR<60 ml/min/1.73m²组2.4% vs 0.8%,eGFR≥60 ml/min/1.73m²组0.6% vs 0.3%。
局限性
- 尿白蛋白-肌酐比值30-300 mg/g亚组的HR存在高度不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In FIDELITY, a prespecified pooled analysis of the FIDELIO-DKD and FIGARO-DKD studies, finerenone was found to improve cardiorenal outcomes in patients with type 2 diabetes, a urine albumin-to-creatinine ratio of 30-5000 mg/g, an estimated glomerular filtration rate (eGFR) of 25 ml/min per 1.73 m2 or more and also receiving optimized renin-angiotensin system blockade treatment. This present analysis focused on the efficacy and safety of finerenone on kidney outcomes. Among 13,026 patients with a median follow-up of three years, finerenone significantly reduced the hazard of a kidney composite outcome (time to kidney failure, sustained 57% or more decrease in eGFR from baseline, or kidney death) by 23% versus placebo (hazard ratio, 0.77; 95% confidence interval, 0.67-0.88), with a three-year absolute between-group difference of 1.7% (95% confidence interval, 0.7-2.6). Hazard ratios were directionally consistent for a prespecified baseline eGFR and urine albumin-to-creatinine ratio categories (Pinteraction = 0.62 and Pinteraction = 0.67, respectively), although there was a high degree of uncertainty in the 30-300 mg/g subgroup. Finerenone significantly reduced the hazard of end-stage kidney disease (ESKD) by 20% versus placebo (0.80; 0.64-0.99). Adverse events were similar between treatment arms, although hyperkalemia leading to treatment discontinuation occurred significantly more frequently with finerenone versus placebo (2.4% vs 0.8% and 0.6% vs 0.3% in patients with eGFR less than 60 vs. greater than or equal to 60 ml/min per 1.73 m2, respectively). Thus, finerenone improved kidney outcomes, reduced the hazard of ESKD, and is well tolerated in patients with chronic kidney disease and type 2 diabetes.
引用
- Bakris GL, Ruilope LM, Anker SD, et al. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2022. PMID: 36367466. doi:10.1016/j.kint.2022.08.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。